Rhythm Biosciences Limited
ASX:RHY Stock Report
Rhythm Biosciences Past Earnings Performance Rhythm Biosciences's earnings have been declining at an average annual rate of -19.8%, while the Healthcare industry saw earnings declining at 3.3% annually. Revenues have been growing at an average rate of 25.6% per year.
Key information
-19.8%
Earnings growth rate
Healthcare Industry Growth 2.4% Revenue growth rate 25.6% Return on equity -790.7% Net Margin -405.7% Last Earnings Update 30 Jun 2024
Recent past performance updates
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Show all updates
Rhythm Biosciences Ltd Appoints Gavin Fox-Smith as Independent Non-Executive Director Effective 2 December 2024 Nov 11
Rhythm Biosciences Limited, Annual General Meeting, Nov 20, 2024 Sep 10
New minor risk - Share price stability Sep 06
New major risk - Financial position Aug 31
New major risk - Shareholder dilution Mar 31
New minor risk - Shareholder dilution Mar 26 Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million. Mar 22
Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million. Feb 09
Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director Dec 29
Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024 Dec 14
New major risk - Share price stability Dec 07
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans? Dec 06
New minor risk - Share price stability Oct 12
New minor risk - Shareholder dilution Sep 13
Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023 Sep 01
New minor risk - Financial data availability Aug 26
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate Aug 09
Executive Chairman recently bought AU$248k worth of stock May 16
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely Apr 11
Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director Jan 31
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation Dec 02
Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited Nov 29
Less than half of directors are independent Nov 16
Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022 Oct 31 Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer
Executive Chairman recently sold AU$6.5m worth of stock Sep 10
Executive Chairman exercised options to buy AU$459k worth of stock. Aug 31
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021) Aug 30
Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers Jul 19
Less than half of directors are independent Apr 27
Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ® Apr 04
Rhythm Biosciences Ltd Announces Executive Changes Feb 25
Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding Jan 06
Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7) Sep 23
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely Jul 19
Non-Executive Director David White has left the company Jul 15
Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial Jun 16
Rhythm Biosciences Betters ColoSTAT Results May 08
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation Mar 03
New 90-day high: AU$1.64 Mar 01
Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site Feb 11
New 90-day high: AU$1.56 Feb 10
Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites Jan 20
New 90-day high: AU$1.38 Jan 15
New 90-day high: AU$0.88 Dec 31
Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit Dec 04
Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares? Dec 03
New 90-day high: AU$0.28 Nov 10
New 90-day high: AU$0.21 Sep 24
Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial Sep 24
New 90-day high - AU$0.20 Sep 15
Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million. Aug 29
Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding Jul 23
Revenue & Expenses Breakdown
How Rhythm Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History ASX:RHY Revenue, expenses and earnings (AUD Millions) Date Revenue Earnings G+A Expenses R&D Expenses 30 Jun 24 2 -7 3 2 31 Mar 24 2 -8 4 3 31 Dec 23 2 -9 5 4 30 Sep 23 3 -8 6 4 30 Jun 23 3 -8 8 4 31 Mar 23 3 -8 7 4 31 Dec 22 3 -8 6 5 30 Sep 22 3 -9 6 5 30 Jun 22 2 -9 6 5 31 Mar 22 2 -9 6 5 31 Dec 21 2 -9 5 5 30 Sep 21 2 -8 4 5 30 Jun 21 1 -7 3 5 31 Mar 21 1 -5 3 3 31 Dec 20 1 -4 3 2 30 Sep 20 1 -4 2 2 30 Jun 20 0 -4 2 2 31 Mar 20 0 -4 2 1 31 Dec 19 1 -3 2 1 30 Sep 19 1 -3 2 1 30 Jun 19 1 -3 3 1 31 Mar 19 1 -3 2 1 31 Dec 18 0 -3 2 1 30 Sep 18 0 -2 2 1 30 Jun 18 0 -2 1 0
Quality Earnings: RHY is currently unprofitable.
Growing Profit Margin: RHY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RHY is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.
Accelerating Growth: Unable to compare RHY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RHY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-25.4%).
Return on Equity
High ROE: RHY has a negative Return on Equity (-790.71%), as it is currently unprofitable.
Return on Capital Employed
Discover strong past performing companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
